Ken Griffin Nurix Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$18.93 - $25.69 $124,938 - $169,554	6,600 Added 68.04%	16,300 $365,000
Q2 2024 Aug 14, 2024	BUY	$12.02 - $21.3 $102,170 - $181,050	8,500 Added 708.33%	9,700 $202,000
Q1 2024 May 15, 2024	SELL	$7.77 - $15.66 $84,693 - $170,694	-10,900 Reduced 90.08%	1,200 $17,000
Q4 2023 Feb 14, 2024	BUY	$4.25 - $10.71 $24,650 - $62,118	5,800 Added 92.06%	12,100 $124,000
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $932,196 - $1.2 Million	-118,600 Reduced 94.96%	6,300 $49,000
Q2 2023 Aug 14, 2023	SELL	$8.7 - $13.28 $241,859 - $369,184	-27,800 Reduced 18.21%	124,900 $1.25 Million
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $82,176 - $127,296	9,600 Added 6.71%	152,700 $1.36 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $617,236 - $913,334	62,600 Added 77.76%	143,100 $1.57 Million
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $389,628 - $625,996	-31,600 Reduced 28.19%	80,500 $1.05 Million

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $942M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.